Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TYMS | P04818 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632480 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL2623807 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL13273272 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL7653783 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL30698170 | 0.91 | RNASE1 (0.61) | RNASE1TK1BCHETYMSUPP1 | |
| SCHEMBL6542150 | 0.91 | RNASE1 (0.61) | RNASE1TK1BCHETYMSUPP1 | |
| SCHEMBL22992340 | 0.89 | RNASE1 (0.82) | RNASE1TK1 | |
| SCHEMBL9326675 | 0.89 | RNASE1 (0.82) | RNASE1TK1 | |
| SCHEMBL13273344 | 0.89 | RNASE1 (0.68) | RNASE1POLBTYMS | |
| SCHEMBL21886791 | 0.89 | RNASE1 (0.82) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | TYMP, DPYD, CXCL8 | RNASE1 1379/4885TK1 19/4885BCHE 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.